5 A multivariate plasma biomarker model enabling safe exclusion of glioblastoma

Clicks: 13
ID: 326712
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #261 of 286 articles by views in journal of neuro-oncology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 286 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Introduction Glioblastoma (GBM) is the most aggressive primary brain tumor and remains difficult to diagnose due to reliance on MRI and invasive biopsies, which are limited by accessibility, morbidity, and radiologic uncertainty. Blood-based biomarkers may provide a minimally-invasive strategy to support early diagnostic-triage. Methods In this retrospective case-control study, plasma samples from 72 patients with newly-diagnosed GBM and 102 age-matched healthy controls were analyzed. Seven circulating proteins were quantified using ultrasensitive- and clinical-grade immunoassays: glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), tau, neuron-specific enolase (NSE), myeloperoxidase (MPO), and polymorphonuclear-(PMN) elastase. Diagnostic performance was assessed using receiver-operating-characteristic (ROC) analysis. Multivariate logistic regression with 10-fold cross-validation and 1,000-iteration bootstrap resampling evaluated model robustness, with emphasis on sensitivity and negative predictive value (NPV) for exclusion-use. Results Among individual plasma biomarkers, GFAP demonstrated near-perfect separation between GBM and controls (AUC = 0.995), followed by NfL (AUC = 0.957), whereas tau, NSE, MPO, and PMN-elastase showed more modest individual performance. A multivariate logistic regression model integrating GFAP, NfL, tau, NSE, MPO, and PMN-elastase achieved near-perfect classification of GBM-versus-controls (AUC = 0.999), outperforming all individual biomarkers. At the optimal probability threshold, sensitivity reached 98.6% with 100% specificity, with no GBM cases misclassified as negative. Ten-fold cross-validation yielded a mean AUC of 0.984 with consistently high-sensitivity and specificity across folds, indicating minimal overfitting. Bootstrap resampling (1,000-iterations) confirmed stability of discriminative performance. When extrapolated to population-level prevalence, the model maintained an extremely high NPV (>0.999), while PPV remained low, consistent with its intended role as a high-sensitivity exclusion tool rather than a confirmatory test. Conclusion A plasma-based multivariate biomarker model enables accurate, safe exclusion of glioblastoma and supports diagnostic triage alongside neuro-imaging.
Reference Key
openalex_W7204450633 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors M Jonathan Decarpentrie, Clara David, Julien Favresse, M Julien Cabo, Fabienne George, Lionel D'hondt, Mattéo Riva, Jonathan Douxfils
Are you one of these authors? Claim your profile
Journal journal of neuro-oncology
Year 2026
DOI
10.1093/neuonc/noag172.008
URL
https://academic.oup.com/neuro-oncology/article-pdf/28/Supplement_1/noag172.008/70805821/noag172.008.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.